• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

负变构调节剂与 I 组代谢型谷氨酸受体结合的亚型选择性机制。

Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.

机构信息

School of Pharmaceutical Sciences, Collaborative Innovation Center for Brain Science and Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, China.

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.

出版信息

Acta Pharmacol Sin. 2021 Aug;42(8):1354-1367. doi: 10.1038/s41401-020-00541-z. Epub 2020 Oct 29.

DOI:10.1038/s41401-020-00541-z
PMID:33122823
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8285414/
Abstract

Group I metabotropic glutamate receptors (mGlu and mGlu) are promising targets for multiple psychiatric and neurodegenerative disorders. Understanding the subtype selectivity of mGlu and mGlu allosteric sites is essential for the rational design of novel modulators with single- or dual-target mechanism of action. In this study, starting from the deposited mGlu and mGlu crystal structures, we utilized computational modeling approaches integrating docking, molecular dynamics simulation, and efficient post-trajectory analysis to reveal the subtype-selective mechanism of mGlu and mGlu to 10 diverse drug scaffolds representing known negative allosteric modulators (NAMs) in the literature. The results of modeling identified six pairs of non-conserved residues and four pairs of conserved ones as critical features to distinguish the selective NAMs binding to the corresponding receptors. In addition, nine pairs of residues are beneficial to the development of novel dual-target NAMs of group I metabotropic glutamate receptors. Furthermore, the binding modes of a reported dual-target NAM (VU0467558) in mGlu and mGlu were predicted to verify the identified residues that play key roles in the receptor selectivity and the dual-target binding. The results of this study can guide rational structure-based design of novel NAMs, and the approach can be generally applicable to characterize the features of selectivity for other G-protein-coupled receptors.

摘要

I 型代谢型谷氨酸受体(mGlu 和 mGlu)是多种精神疾病和神经退行性疾病的有希望的靶点。了解 mGlu 和 mGlu 变构位点的亚型选择性对于设计具有单一或双重作用机制的新型调节剂至关重要。在这项研究中,我们从已发表的 mGlu 和 mGlu 晶体结构出发,利用整合对接、分子动力学模拟和高效后轨迹分析的计算建模方法,揭示了 mGlu 和 mGlu 对 10 种不同药物支架的亚型选择性机制,这些药物支架代表了文献中已知的负变构调节剂(NAMs)。建模结果确定了六对非保守残基和四对保守残基作为区分相应受体选择性 NAMs 结合的关键特征。此外,有九对残基有利于开发新型 I 型代谢型谷氨酸受体的双重靶标 NAMs。此外,还预测了报告的双重靶标 NAM(VU0467558)在 mGlu 和 mGlu 中的结合模式,以验证在受体选择性和双重靶标结合中起关键作用的鉴定残基。这项研究的结果可以指导新型 NAMs 的合理基于结构的设计,并且该方法可以普遍适用于表征其他 G 蛋白偶联受体的选择性特征。

相似文献

1
Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.负变构调节剂与 I 组代谢型谷氨酸受体结合的亚型选择性机制。
Acta Pharmacol Sin. 2021 Aug;42(8):1354-1367. doi: 10.1038/s41401-020-00541-z. Epub 2020 Oct 29.
2
Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity.对负变构调节剂与代谢型谷氨酸受体5相互作用的深入研究:发现及对一系列具有纳摩尔亲和力的新型配体的计算建模
Bioorg Med Chem. 2015 Jul 1;23(13):3040-58. doi: 10.1016/j.bmc.2015.05.008. Epub 2015 May 12.
3
Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family.变构结合位点和 C 类 G 蛋白偶联受体的激活机制:代谢型谷氨酸受体家族。
AAPS J. 2015 May;17(3):737-53. doi: 10.1208/s12248-015-9742-8. Epub 2015 Mar 12.
4
Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations.通过分子动力学模拟探索代谢型谷氨酸受体 5 负变构调节剂在临床试验中的结合机制。
ACS Chem Neurosci. 2018 Jun 20;9(6):1492-1502. doi: 10.1021/acschemneuro.8b00059. Epub 2018 Mar 16.
5
Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.鉴定代谢型谷氨酸受体亚型 5 的新型变构调节剂,其作用部位与 2-甲基-6-(苯乙炔基)吡啶结合部位不同。
ACS Chem Neurosci. 2019 Aug 21;10(8):3427-3436. doi: 10.1021/acschemneuro.8b00227. Epub 2019 Jun 17.
6
Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology.严格表征人类代谢型谷氨酸受体 1 的变构调节作用,揭示了探针和检测依赖的药理学。
Mol Pharmacol. 2023 Jun;103(6):325-338. doi: 10.1124/molpharm.122.000664. Epub 2023 Mar 15.
7
Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.动力学和系统偏差作为代谢型谷氨酸受体 5 变构调节剂药理学的驱动力。
Neuropharmacology. 2019 May 1;149:83-96. doi: 10.1016/j.neuropharm.2019.02.005. Epub 2019 Feb 11.
8
Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.基于片段的计算机整合药物设计:代谢型谷氨酸受体 5 的变构调节剂案例研究。
AAPS J. 2017 Jul;19(4):1235-1248. doi: 10.1208/s12248-017-0093-5. Epub 2017 May 30.
9
Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.I 型代谢型谷氨酸受体的变构调节剂:新型亚型选择性配体及治疗前景。
Curr Opin Pharmacol. 2002 Feb;2(1):43-9. doi: 10.1016/s1471-4892(01)00119-9.
10
Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.代谢型谷氨酸受体的变构调节剂:从mGlu1、mGlu2和mGlu5增强剂及拮抗剂中获得的经验教训。
Biochem Soc Trans. 2004 Nov;32(Pt 5):881-7. doi: 10.1042/BST0320881.

引用本文的文献

1
Identification of Potential Inhibitors Targeting Non-Structural Proteins NS3 and NS5 of Dengue Virus Using Docking and Deep Learning Approaches.使用对接和深度学习方法鉴定针对登革病毒非结构蛋白NS3和NS5的潜在抑制剂
Pharmaceuticals (Basel). 2025 Apr 13;18(4):566. doi: 10.3390/ph18040566.
2
Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders.大麻素:在神经退行性疾病中与维生素B12联合使用时的调节和增强潜力。
Pharmaceuticals (Basel). 2024 Jun 20;17(6):813. doi: 10.3390/ph17060813.
3
Possible molecular exploration of herbal pair Haizao-Kunbu in the treatment of Graves' disease by network pharmacology, molecular docking, and molecular dynamic analysis.基于网络药理学、分子对接和分子动力学分析探讨海藻昆布药对治疗 Graves 病的潜在分子机制。
Front Endocrinol (Lausanne). 2023 Oct 4;14:1236549. doi: 10.3389/fendo.2023.1236549. eCollection 2023.
4
Computational Insights into Natural Antischistosomal Metabolites as SmHDAC8 Inhibitors: Molecular Docking, ADMET Profiling, and Molecular Dynamics Simulation.天然抗血吸虫代谢产物作为SmHDAC8抑制剂的计算洞察:分子对接、ADMET分析和分子动力学模拟
Metabolites. 2023 May 15;13(5):658. doi: 10.3390/metabo13050658.
5
Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (M) using molecular docking and deep learning methods.利用分子对接和深度学习方法鉴定药用植物来源的植物化学物质作为 SARS-CoV-2 主蛋白酶(M)的潜在抑制剂。
Comput Biol Med. 2023 May;157:106785. doi: 10.1016/j.compbiomed.2023.106785. Epub 2023 Mar 11.
6
In Vitro and In Silico Studies of Kinase Inhibitor of MAPK3 Protein to Determine Leishmania martiniquensis Treatment.体外和计算机模拟研究 MAPK3 蛋白激酶抑制剂,以确定治疗马丁尼奎亚利什曼原虫。
Acta Parasitol. 2023 Mar;68(1):240-248. doi: 10.1007/s11686-023-00659-0. Epub 2023 Jan 13.
7
Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain.分子动力学模拟突出了 Delta 和奥密克戎变异株与 SARS-CoV-2 原始株相比,棘突-ACE2 界面的结合位景观发生了改变。
Comput Biol Med. 2022 Oct;149:106035. doi: 10.1016/j.compbiomed.2022.106035. Epub 2022 Aug 27.
8
Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?靶向代谢型谷氨酸受体5:神经退行性疾病的潜在治疗策略?
Front Pharmacol. 2022 May 11;13:893422. doi: 10.3389/fphar.2022.893422. eCollection 2022.
9
Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study.姜黄素抑制新型 SARS-CoV-2 关注变异株(VOC)奥密克戎的刺突蛋白:一项计算机模拟研究。
Comput Biol Med. 2022 Jul;146:105552. doi: 10.1016/j.compbiomed.2022.105552. Epub 2022 Apr 27.
10
VARIDT 2.0: structural variability of drug transporter.VARIDT 2.0:药物转运体的结构变异性。
Nucleic Acids Res. 2022 Jan 7;50(D1):D1417-D1431. doi: 10.1093/nar/gkab1013.

本文引用的文献

1
NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data.NOREVA:时间进程和多类代谢组学数据的增强标准化和评估。
Nucleic Acids Res. 2020 Jul 2;48(W1):W436-W448. doi: 10.1093/nar/gkaa258.
2
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.大环多肽对HDAC1的选择性抑制用于治疗胶质母细胞瘤:基于分子动力学的结合机制分析
Front Mol Biosci. 2020 Mar 11;7:41. doi: 10.3389/fmolb.2020.00041. eCollection 2020.
3
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics.治疗靶点数据库 2020 年版:一个丰富的资源,有助于靶向治疗的研究和早期开发。
Nucleic Acids Res. 2020 Jan 8;48(D1):D1031-D1041. doi: 10.1093/nar/gkz981.
4
VARIDT 1.0: variability of drug transporter database.VARIDT 1.0:药物转运体数据库的变异性
Nucleic Acids Res. 2020 Jan 8;48(D1):D1171. doi: 10.1093/nar/gkz878.
5
Identification of the gene signature reflecting schizophrenia's etiology by constructing artificial intelligence-based method of enhanced reproducibility.通过构建基于人工智能的增强可重复性方法,识别反映精神分裂症病因的基因特征。
CNS Neurosci Ther. 2019 Sep;25(9):1054-1063. doi: 10.1111/cns.13196. Epub 2019 Jul 27.
6
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design.基于 MM/PBSA 和 MM/GBSA 的终点结合自由能计算:在药物设计中的策略与应用。
Chem Rev. 2019 Aug 28;119(16):9478-9508. doi: 10.1021/acs.chemrev.9b00055. Epub 2019 Jun 24.
7
Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data.通过综合转录组数据集的新型特征选择策略,确定精神分裂症的一致基因特征。
Brief Bioinform. 2020 May 21;21(3):1058-1068. doi: 10.1093/bib/bbz049.
8
Computational Studies on the Potency and Selectivity of PUGNAc Derivatives Against GH3, GH20, and GH84 β-N-acetyl-D-hexosaminidases.PUGNAc衍生物对GH3、GH20和GH84β-N-乙酰-D-己糖胺酶的效力和选择性的计算研究
Front Chem. 2019 Apr 12;7:235. doi: 10.3389/fchem.2019.00235. eCollection 2019.
9
Allosteric Modulation Mechanism of the mGluR Transmembrane Domain.代谢型谷氨酸受体跨膜结构域的变构调节机制
J Chem Inf Model. 2019 Jun 24;59(6):2871-2878. doi: 10.1021/acs.jcim.9b00045. Epub 2019 May 3.
10
Interactive Tree Of Life (iTOL) v4: recent updates and new developments.交互式生命树 (iTOL) v4:最新更新和新发展。
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259. doi: 10.1093/nar/gkz239.